Fixed drug eruption induced by Etoricoxib in Thailand: A case report
Year: 2025
Type: article
Study design: Case Report
Abstract: Etoricoxib, a commonly prescribed non-steroidal anti-inflammatory drug (NSAID), has been associated with adverse cutaneous reactions, including fixed drug eruption (FDE). We describe a case report of a 37-year-old Thai male who developed erythematous plaques and bullous lesions following the ingestion of a 90 mg dose of Etoricoxib. The lesions were located on the lateral aspect of the right leg near the popliteal fossa, the dorsal aspect of the right foot, the medial aspect of the right arm, and the left lumbar region. Symptoms began two hours post-ingestion with pruritus, progressing to erythema and bullous formation over the subsequent 72 h. The patient was treated with oral Prednisolone, antihistamines, and topical steroids, resulting in significant clinical improvement within 12 days. This case highlights the potential of Etoricoxib to trigger generalized bullous fixed drug eruption (GBFDE), which is a more severe variant involving more than three body sites and classified as one of the Severe Cutaneous Adverse Reactions (SCARs), emphasizing the need for prompt recognition and appropriate management to prevent recurrence and mitigate symptoms. • Etoricoxib triggered generalized bullous fixed drug eruption (GBFDE) in a patient. • Lesions developed on multiple sites within 2 h of Etoricoxib ingestion. • Oral Prednisolone and topical steroids led to significant recovery within 12 days. • Study underscores importance of early recognition and drug discontinuation. • Patient advised to avoid COX-2 inhibitors to prevent recurrence of FDE.
Source: Toxicology Reports
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,530
OpenAlex ID: W4408838538